The project in a nutshell
Evaluating the use of drugs to help make prostate cancer cells
more susceptible to radiation therapy in combination with a marker
that targets the radiation to prostate cancer cells.
Why we funded it
Although radiotherapy is widely used in
treating prostate cancer patients, damage to neighbouring normal
organs and cells limits the radiation dose which can be delivered.
Significantly, there is no curative treatment for prostate cancer
that has spread (metastasised).
Targeted radiotherapy enables the delivery of
radiation selectively to cancerous sites while not harming normal
tissue. The combination of this targeted approach with the
administration of drugs that make the prostate cancer cells more
susceptible to radiation is expected to provide the optimal
treatment for patients with prostate cancer that has spread.
For more detailed information on this project,
please look at the lay summary